<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607265</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0838</org_study_id>
    <nct_id>NCT04607265</nct_id>
  </id_info>
  <brief_title>Sudden Death Stratification</brief_title>
  <official_title>Channel Detection to Predict Ventricular Arrhythmia in Patients With Non-ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sudden cardiac death (SCD) risk stratification is a challenge in non-ischemic cardiomyopathy&#xD;
      (NICM). The underlying mechanism of monomorphic ventricular tachycardia (VT) is mostly scar&#xD;
      related. While electrophysiological mechanisms underlying ventricular arrhythmia are well&#xD;
      known, late gadolinium enhanced (LGE) cardiac MRI-3D reconstructions are now able to guide VT&#xD;
      ablation procedures. Such exam may help in identifying specific properties of scar at risk of&#xD;
      malignant arrhythmia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detect pro arrhythmogenic scar characteristics</measure>
    <time_frame>baseline : collected at the time of the cardiac MRI</time_frame>
    <description>The outcomes will aim to provide scar characteristics from 3D cardiac MRI reconstructions to detect pro arrhythmic properties in NICM patients. Comparisons between NICM patients who experienced VT ablation and NICM patients without history of ventricular arrhythmia will be made.&#xD;
In both groups, Primary outcome will aim to measure the number of the conducting channels into scars (n).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Ventricular tachycardia (VT) group</arm_group_label>
    <description>NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Comparison of scar characteristics on cardiac MRI between the two groups.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Ventricular tachycardia (VT) group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that underwent VT ablation, had a cardiac MRI prior to the ablation and suffered&#xD;
        from non-ischemic cardiomyopathy (NICM) were included in the VT group. A 2:1 ratio of&#xD;
        patients with non-ischemic cardiomyopathy and no history of ventricular tachycardia were&#xD;
        included in the control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult with NICM&#xD;
&#xD;
          -  Previous history of ventricular tachycardia (VT) and no previous history of VT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inherited cardiomyopathies&#xD;
&#xD;
          -  Previous history of myocarditis WITHOUT oedema/scar at the MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LGE MRI</keyword>
  <keyword>Ventricular tachycardia</keyword>
  <keyword>sudden cardiac death</keyword>
  <keyword>non-ischemic cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

